Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery
ConditionPancreatic Adenocarcinoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-79
SponsorHamilton Health Sciences Corporation
About this trial
This is a single-arm, single-center feasibility trial of patients with borderline resectable pancreatic adenocarcinoma receiving chemotherapy with mFOLFIRINOX or gemcitabine / nab-paclitaxel followed by pancreatectomy.
Eligibility criteria
Qualifiers
1. Men and women 18 years of age or older who present with biopsy proven borderline resectable pancreatic adenocarcinoma who are medically fit for surgery as per assessment by treating surgeon.
Absolute neutrophil count (ANC) = or > 1500, platelets > 100K
Total bilirubin <1.5x upper limit of normal (ULN)
Alanine transaminase (ALT), Aspartate aminotransferase (AST) < 3 x ULN
Disqualifiers
Proven metastatic disease (e.g. on imaging modality such as CT scan of the chest, abdomen and pelvis or MRI)
Locally advanced pancreatic cancer (see definition section 3.3)
Prior treatment with radiation therapy to the pancreas or associated field.
Contraindications to receive chemotherapy
Trial design
Treatments tested in this trial
- mFOLFIRINOX
- Gemcitabine / Nab-paclitaxel
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov